More than 63% of hidradenitis suppurativa (HS) patients who took bimekizumab (Bimzelx, UCB) for two years had no or mild skin pain, a substantial improvement from 10% at baseline. Of 425 HS patients with one or more draining tunnel (DT) at baseline, 55.7% had no DTs at two years of treatment. Christopher Sayed, MD, a Dermatologist at the University of North Carolina Chapel Hill’s HS Clinic in Durham, NC, discusses the results of the study, which were presented at the American Academy of Dermatology’s 2025 Annual Meeting in Orlando, FL.
